Retinitis pigmentosa (rp)
Drug research and approvals for retinitis pigmentosa (rp): what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 16, 2026, 16 studies of retinitis pigmentosa (rp) are recruiting on ClinicalTrials.gov, Health Canada has authorized 6 drug trials for it since 2013, and FDA has 0 approved and 51 open orphan designations naming it.
- Recruiting worldwide: 16
- Trials authorized in Canada: 6
- FDA orphan approvals: 0
- EU medicines: 0
Recruiting Now
Newest start dates first, of 16 recruiting on ClinicalTrials.gov ↗- Brain Stimulation Effects on Orientation and Mobility Skills in Adults With Vision ImpairmentNCT07341763 · Not applicable · University of Waterloo · starts Nov 1, 2026
- A 24-Month Trial of NPI-001 for the Preservation of Photoreceptors in Retinitis Pigmentosa Associated With Usher…NCT07710196 · Phase 3 · Nacuity Pharmaceuticals, Inc. · starts Oct 23, 2026
- Safety Evaluation Study of Pitavastatin PLGA Nano-particle for Retinitis PigmentosaNCT07774975 · Phase 1 · Kyushu University · starts Oct 1, 2026
- Study to Evaluate the Efficacy of a Single Intravitreal Injection of RTx-015 in Participants With Retinitis Pigmentosa…NCT07901751 · Phase 2 / Phase 3 · Ray Therapeutics, Inc. · starts Oct 1, 2026
- Restoration of Central Vision With PRIMA in Patients With Photoreceptor DegenerationNCT07266584 · Not applicable · Science Corporation · starts Apr 22, 2026
- Observational Study to Investigate the Short-term Effects of Transcorneal Electrical Stimulation on Visual PerformanceNCT07548944 · Not reported · Okuvision GmbH · starts Apr 20, 2026
- A Study to Investigate the Safety of DSP-3077 After a Unilateral Eye Injection in Male and Female Participants 18 Years…NCT06891885 · Phase 1 / Phase 2 · Sumitomo Pharma America, Inc. · starts Apr 16, 2026
- A Phase 1/2 Study in Healthy Volunteers and Participants With Autosomal Dominant Retinitis Pigmentosa (RHO-adRP)NCT07408232 · Phase 1 / Phase 2 · Octant, Inc. · starts Mar 10, 2026
- Implementation and Evaluation of a Post-Diagnostic Announcement Protocol at the CRMR RefeRet, Quinze-Vingts HospitalNCT07292987 · Not applicable · Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts · starts Dec 1, 2025
- Natural History Study of Patients With EYS-Associated RPNCT07228793 · Not reported · Sensor Technology for Deafblind · starts Nov 7, 2025
Trials Authorized in Canada
Newest first; search them all in Canada trials| Oct 16, 2024 | A two-year double-masked, randomized, sham-controlled study to evaluate the efficacy, safety and tolerability of ultevursen in subjects with retinitis…ULTEVURSEN | LABORATOIRES THÉA | Ongoing |
| Aug 23, 2024 | A phase 3, multi-center, randomized study to assess the efficacy, safety and tolerability of subretinal ocu400 gene therapy for the treatment of retinitisOCU400 | OCUGEN | Ongoing |
| Apr 29, 2022 | A double-masked, randomized, controlled, multiple-dose study to evaluate the efficacy, safety and tolerability of qr-421a in subjects with retinitis pigmentosa…QR-421A | PROQR THERAPEUTICS IV BV | Pending |
| Dec 2, 2021 | Phase 3 follow-up study of aav5-hrkp.rpgr for the treatment of x-linked retinitis pigmentosa associated with variants in the rpgr geneAAV5-HRKP.RPGR/ TRIAMCINOLONE ACETONIDE | Johnson & Johnson | Ongoing |
| Sep 29, 2021 | An open-label extension study to evaluate the safety and tolerability of qr-421a in subjects' with retinitis pigmentosa (rp) due to mutations in exon 13 of the…QR-421A | PROQR THERAPEUTICS | Closed |
| Feb 15, 2019 | A first-in-human study (fih) to evaluate the safety and tolerability of qr-421a in subjects with retinitis pigmentosa (rp) due to mutations in exon 13 of the…QR-421A | PROQR THERAPEUTICS IV BV | Closed |
FDA Orphan Designations
Approved first, then open designations, newest first; 15 of 51| Oct 26, 2026 | small molecule corrector of rhodopsintreatment of retinitis pigmentosa | Octant, Inc. | Designated |
| Sep 23, 2026 | AAV-mediated anti-PROX1 gene therapy…treatment of retinitis pigmentosa | Celliaz Ltd. | Designated |
| Mar 26, 2026 | retinal cells derived from allogeneic human induced…treatment of retinitis pigmentosa | Agnos Therapeutics, Inc. | Designated |
| Mar 23, 2026 | tripentadecanointreatment of retinitis pigmentosa | SunRegen Healthcare AG | Designated |
| Mar 12, 2026 | allogeneic self-organized three-dimensional retinal…treatment of retinitis pigmentosa | Sumitomo Pharma America Inc | Designated |
| Feb 14, 2026 | a cell-based therapeutic composed of purified human rod…treatment of retinitis pigmentosa | InGel Therapeutics Inc. | Designated |
| Dec 10, 2025 | allogeneic human induced pluripotent stem cell-derived…treatment of retinitis pigmentosa | BlueRock Therapeutics LP | Designated |
| May 1, 2025 | recombinant adeno-associated virus vector expressing…treatment of retinitis pigmentosa | Bionic Sight, Inc. | Designated |
| Apr 16, 2025 | N6-(3-aminopropyl)-L-lysine trihydrochloridetreatment of retinitis pigmentosa | Ren Bioscience LLC | Designated |
| Mar 3, 2025 | adeno-associated virus vector with a codon-optimized…treatment of retinitis pigmentosa | GenAns Biotechnology Co., Ltd | Designated |
| Oct 28, 2024 | recombinant human adeno-associated virus serotype 2…treatment of retinitis pigmentosa | Zhongmou Therapeutics, Inc. | Designated |
| Sep 25, 2024 | adeno associated virus carrying opn3treatment of retinitis pigmentosa | NeoVec Biotherapeutics Inc. | Designated |
| Sep 23, 2024 | recombinant adeno-associated virus 5 vector expressing a…treatment of autosomal recessive retinitis pigmentosa due to CNGB1 mutations | National Institutes of Health National Institutes of Health (NIH), National Center for Advancing Translational Sciences (NCATS) | Designated |
| Aug 20, 2024 | adeno-associated virus (AAV) gene therapy product that…treatment of retinitis pigmentosa | Skyline Therapeutics (US) Inc. | Designated |
| Mar 20, 2024 | Human induced pluripotent stem cells (iPSC)-derived…Treatment of Retinitis Pigmentosa | iRegene Therapeutics Co., Ltd | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA